- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04031612
Neoadjuvant Database (NEOADJ)
Prospective and Retrospective Neoadjuvant Breast Cancer Database
The NEOADJ Database base contains data collected during the regular clinical patient management (sociodemographic, clinical, pathological, radiological, biological, disease evolution...). This database allows easy access to information in a centralized and structured way.
This cohort is used to gather insights for research purposes. All data collected come from medical files of patients managed at Centre Georges Francois Leclerc, Dijon, France.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: AURELIE BERTAUT, MD, PhD
- Phone Number: +33 3 80 73 77 84
- Email: ABertaut@cgfl.fr
Study Locations
-
-
-
Dijon, France
- Recruiting
- Methodology, Biostatistics and Data Management Unit
-
Contact:
- AURELIE BERTAUT
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women followed for breast cancer in Georges Francois Leclerc Center
- Neoadjuvant chemotherapy
- Age >= 18
Exclusion Criteria:
- Males
- Metastatic breast cancer
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Neoadjuvant Breast Cancer
Patients undergoing neoadjuvant therapy for breast cancer
|
Neoadjuvant therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient survival
Time Frame: 5 years
|
Overall survival and evolution over years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Collection of patient and treatment characteristics
Time Frame: 5 years
|
Collection of patient and treatment characteristics over years, to set up prospective and retrospective studies
|
5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AB2009SEIN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoadjuvant Treatment in Breast Cancer
-
Tianjin Medical University Cancer Institute and...Not yet recruitingNeoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
-
University of Eastern PiedmontRecruiting
-
Guangdong Provincial People's HospitalNot yet recruitingNeoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
-
Affiliated Cancer Hospital & Institute of Guangzhou...RecruitingNeoadjuvant Treatment for Locally Advanced Cervical CancerChina
-
Zhejiang Cancer HospitalUnknownEvaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast CancerChina
-
Henan Cancer HospitalRecruitingEsophageal Cancer | Surgery | Survival | Neoadjuvant TreatmentChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingTreatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA MutationChina
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruitingPatients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy
-
University of WashingtonNational Cancer Institute (NCI)CompletedDepression | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Anxiety Disorder | Psychosocial Effects of Cancer and Its Treatment | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in SituUnited States
-
Hubei Cancer HospitalRecruitingBreast Cancer | Implant Breast Reconstruction | Neoadjuvant RadiotherapyChina
Clinical Trials on Neoadjuvant therapy
-
Yongtao HanCompletedEsophageal Squamous Cell Carcinoma (ESCC)China
-
Wenjin YinActive, not recruitingBreast Cancer InvasiveChina
-
Tianjin Medical University Cancer Institute and...Not yet recruitingNeoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
-
Universitas AirlanggaNot yet recruitingBreast Cancer | Breast Neoplasm Female | Locally Advanced Breast Cancer | Locally Advanced Breast Cancer (LABC)
-
London Health Sciences Centre Research Institute...Active, not recruitingLocally Advanced Breast Cancer | High-Risk CancerCanada
-
Institute of Oncology LjubljanaActive, not recruiting
-
Guangxi Medical UniversityRecruiting
-
First Affiliated Hospital of Zhejiang UniversityRecruitingHR Positive/HER2 Low Breast CancerChina
-
Tang-Du HospitalRecruitingEsophageal Squamous Cell Carcinoma | Neoadjuvant | IvonescimabChina
-
Minia UniversityCompletedSurgery | Resectable Pancreatic Cancer | Neoadjuvant Chemotherapy | ManagementEgypt